Indications of Ivosidenib

Ivosidenib (Ivosidenib) is an IDH1 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) who express IDH1 gene mutations. AML is a subtype of leukemia caused by the abnormal proliferation of malignant clonal cells in the bone marrow, and mutations in the IDH1 gene are one of the specific genetic abnormalities.

An indication is the specific disease or condition that a drug is designed and approved to treat. In this regard, the indications for ivonib mainly include subtypes of AML patients with mutations in the IDH1 gene. IDH1gene mutations lead to abnormal activation of IDH1 enzyme, thereby promoting the development of AML.

Avosidenib blocks the metabolic process in leukemia cells by specifically inhibiting the abnormal activity ofIDH1 enzyme, slowing down or stopping the growth and proliferation of these cells. This targeted therapy strategy makes ivonib an innovative option in the treatment of AML, especially for patients whose needs cannot be met by traditional treatments.

When patients take ivonib, they usually need to undergo IDH1 gene mutation testing to ensure that their genotype meets the indications of the drug. During treatment, doctors will develop a personalized treatment plan based on the patient's specific conditions and conduct regular monitoring to evaluate the efficacy of the drug and the patient's safety.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.